Tumor immune microenvironment is associated with the growth of intracranial germinomas.
Adolescent
Adult
B7-H1 Antigen
/ metabolism
Brain Neoplasms
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Child
Combined Modality Therapy
Female
Follow-Up Studies
Germinoma
/ immunology
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Prognosis
Survival Rate
Tumor Microenvironment
/ immunology
Germ cell tumor
Intracranial germinoma
PD-1
PD-L1
Tumor immune microenvironment
Tumor-infiltrating lymphocyte
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
01
10
2019
accepted:
22
11
2019
pubmed:
28
11
2019
medline:
10
6
2020
entrez:
28
11
2019
Statut:
ppublish
Résumé
The role of immune checkpoint molecules and the tumor immune microenvironment in the development of intracranial germ cell tumors remains unclear. We investigated the expression of programed cell death-1 (PD-1), programed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TILs) in 8 patients who had intracranial germinomas with sufficient tumor tissue by immunohistochemistry, to analyze the associations between their clinical courses and radiological features. The 8 patients were categorized based on the duration between symptom onset and pathological diagnosis into the long-term onset (LTO) group (> 1 year of symptoms) and the short-term onset (STO) group (< 1 year of symptoms). Three patients belonged to the LTO group and 5 patients to the STO group. Compared with STO tumors, LTO tumors were significantly associated with a lower ratio of PD-L1-positive tumor cells (p = 0.012), higher number of infiltrating CD3- and CD8-positive lymphocytes (p = 0.016, 0.003, respectively), and lower ratio of PD-1-positive cells per CD8-positive lymphocytes (p = 0.047). LTO germinomas were significantly smaller in size than STO tumors, not associated with hydrocephalus, and tended to be present in patients with older age at diagnosis and atypical tumor location. Our data suggest that the tumor immune microenvironment, including PD-1/PD-L1 signaling, is associated with the growth of intracranial germinomas.
Identifiants
pubmed: 31773448
doi: 10.1007/s11060-019-03355-0
pii: 10.1007/s11060-019-03355-0
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-146Références
Clin Dermatol. 2013 Mar-Apr;31(2):191-9
pubmed: 23438382
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Neuroreport. 2009 Dec 9;20(18):1597-602
pubmed: 19875977
Ann Oncol. 2016 Feb;27(2):300-5
pubmed: 26598537
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Oncologist. 2008 Jun;13(6):690-9
pubmed: 18586924
PLoS One. 2018 Apr 4;13(4):e0194594
pubmed: 29617441
Cancer Sci. 2017 May;108(5):1000-1006
pubmed: 28266091
J Neurosurg. 1985 Aug;63(2):155-67
pubmed: 2991485
J Neurooncol. 2018 Sep;139(2):251-259
pubmed: 29675794
J Neuropathol Exp Neurol. 2018 Feb 1;77(2):119-127
pubmed: 29237087
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Clin Cancer Res. 2005 Apr 15;11(8):2947-53
pubmed: 15837746
Oncotarget. 2017 Mar 28;8(13):21794-21805
pubmed: 28423520
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):639-47
pubmed: 22361082
Cancer Immunol Immunother. 2007 Aug;56(8):1173-82
pubmed: 17186290
Eur J Cancer. 1998 Jan;34(1):104-10
pubmed: 9624246
Neurosurg Rev. 2014 Jul;37(3):445-50; discussion 451
pubmed: 24715277
Chemotherapy. 2017;62(6):374-380
pubmed: 29045938
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
J Clin Oncol. 1999 Aug;17(8):2585-92
pubmed: 10561326
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9
pubmed: 15569934
Oncotarget. 2015 May 10;6(13):11139-49
pubmed: 25871477
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Acta Histochem. 2006;108(1):19-24
pubmed: 16530813
Jpn J Radiol. 2015 Jun;33(6):336-43
pubmed: 25943790
Neuro Oncol. 2015 Aug;17(8):1064-75
pubmed: 25355681
Pediatr Blood Cancer. 2016 Aug;63(8):1461-4
pubmed: 27135656
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1449-56
pubmed: 20045266
J Neurooncol. 2017 Jun;133(2):277-285
pubmed: 28447277
Br J Cancer. 2015 Jul 28;113(3):411-3
pubmed: 26171934
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Neurosurg. 1991 Apr;74(4):545-51
pubmed: 1848284
J Neurooncol. 2016 Mar;127(1):173-80
pubmed: 26744133
Cancer. 2017 Dec 15;123(24):4823-4831
pubmed: 28832979
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Childs Nerv Syst. 2002 Feb;18(1-2):30-7
pubmed: 11935241
Oncoimmunology. 2016 Sep 20;5(11):e1235107
pubmed: 27999753
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131